Elan Gorshein, DO, JD, MPH
Assistant Professor of Medicine (Hematology)Cards
About
Research
Publications
2024
Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma
Browning S, Li F, Theprungsirikul P, Parker T, Bar N, Giri S, Anderson T, Stevens E, Gorshein E, Sabbath K, Wei C, Ali S, Witt D, Persico J, Talsania A, Rahmat L, Kidwai W, Legare R, LaSala J, Austin M, Neparidze N. Real-World Efficacy and Patient-Reported Quality of Life Outcomes with Daratumumab Regimens in Multiple Myeloma. Blood 2024, 144: 7831. DOI: 10.1182/blood-2024-204150.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaInternational Myeloma Working GroupAdverse eventsGlobal health statusFunctional scalesMultiple symptom scalesPartial responseProteasome inhibitorsMultiple myelomaHealth statusEastern Cooperative Oncology Group performance statusClinical trialsMonoclonal antibody targeting CD38Median progression free survivalRelapsed/refractory multiple myeloma patientsIntroduction of novel therapiesHealth-related quality of lifeClinical response assessmentDaratumumab-based regimensProgression free survivalInfusion-related reactionsLines of therapyPatient-reported quality of life outcomesMean fatigue scoreHealth-related qualityPrevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original Research
2023
Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population
Traore K, Taneja A, Gorshein E, Castro F, Derkach A, Martinez J, Serrano E, Lesokhin A, Ahlstrom J, Block T, Hydren J, Usmani S, Shah U. Dietary Patterns Among Individuals with Plasma Cell Disorders Compared to the General US Population. Blood 2023, 142: 7363. DOI: 10.1182/blood-2023-186913.Peer-Reviewed Original ResearchBody mass indexPlasma cell disordersHigher HEI scoresFood frequency questionnaireGeneral US populationHEI scoresDietary patternsTotal fruit consumptionMultiple myelomaUS populationDietary interventionDietary guidelinesFruit consumptionCell disordersHealthy dietBlock Food Frequency QuestionnaireElevated body mass indexLower body mass indexCancer-specific mortalityLong-term outcomesHealthy Eating IndexNutrition Examination SurveyHealthy dietary habitsRole of nutritionOlder age groups“Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation
Chen P, Gorshein E, Tormey C, Siddon A, Perincheri S. “Double‐hit” ineffective erythropoiesis—concurrent β‐thalassemia with α‐gene triplication and myelodysplastic syndrome with SF3B1 mutation. American Journal Of Hematology 2023, 98: 984-988. PMID: 36688500, DOI: 10.1002/ajh.26856.Peer-Reviewed Educational Materials
2021
Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center
Dosani T, Poteraj A, Parker T, Bar N, Browning S, Gorshein E, Anderson T, Insogna K, Neparidze N. Use of Denosumab after Zoledronic Acid in Patients with Multiple Myeloma: Real-World Experience from 2015 to 2019 at Yale Cancer Center. Blood 2021, 138: 4756. DOI: 10.1182/blood-2021-147466.Peer-Reviewed Original ResearchBone-modifying agentsUse of denosumabYale Cancer CenterZoledronic acidMultiple myelomaMM patientsCancer CenterMedian numberPhysician preferenceCommon reasonClinical practiceNew fracturesNuclear factor kappa-B ligandStudy periodApproval of denosumabEfficacy of denosumabIncidence of SREsMain treatment centreSmilow Cancer HospitalSuppress bone turnoverPatient's renal functionBone resorption markersCohort of patientsGlomerular filtration rateDate of diagnosisOutcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value
2019
Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience
Krakora R, Shih W, Popli P, Gorshein E, Salaru G, David K, Bannerji R. Impact of Insurance Status on Survival Outcomes in Adults with Acute Lymphoblastic Leukemia (ALL): A Single Center Experience. Blood 2019, 134: 5071. DOI: 10.1182/blood-2019-129390.Peer-Reviewed Original ResearchProgression-free survivalAllogeneic stem cell transplantAcute lymphoblastic leukemiaTime of diagnosisAchievement of CRBetter overall survivalOverall survivalComplete remissionInsurance statusAcute myeloblastic leukemiaSurvival outcomesLymphoblastic leukemiaRegeneron PharmaceuticalsHealth insuranceSurvival rateSingle comprehensive cancer centerBetter progression-free survivalWorse progression-free survivalProportional hazards regression methodsPhiladelphia chromosome statusSingle-center experienceRetrospective chart reviewStem cell transplantComprehensive cancer centerLack of insurance
2017
Unusual Case of Esophageal Adenocarcinoma With Forearm Soft Tissue Metastasis
John E, Gorshein E, Dayan M, Katz K, Malhotra U. Unusual Case of Esophageal Adenocarcinoma With Forearm Soft Tissue Metastasis. The American Journal Of Gastroenterology 2017, 112: s901. DOI: 10.14309/00000434-201710001-01664.Peer-Reviewed Original Research
2016
Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental?
Zelefsky M, Kollmeier M, Gorshein E, Pei X, Torres M, McBride S, Happersett L, Cohen G, Yamada Y. Hip-related toxicity after prostate radiotherapy: Treatment related or coincidental? Radiotherapy And Oncology 2016, 121: 109-112. PMID: 27756494, PMCID: PMC5546832, DOI: 10.1016/j.radonc.2016.08.010.Peer-Reviewed Original ResearchConceptsDegenerative joint diseaseHip painPersistent hip painSevere hip painLocalized prostate cancerOnly variableProstate cancer patientsExternal beam radiotherapyHip revision surgerySalvage therapySevere painCancer patientsProstate cancerJoint diseaseLower incidenceBeam radiotherapyHip replacementConcurrent ADTMultivariate analysisPatientsRadiotherapyPainProstate radiotherapyIncidenceAmbulationA Difficult Position: Appendicitis in Platelet Refractory, Severely Neutropenic Patient
Ha K, Gorshein E, John E, Gharibo M. A Difficult Position: Appendicitis in Platelet Refractory, Severely Neutropenic Patient. The American Journal Of Gastroenterology 2016, 111: s667. DOI: 10.14309/00000434-201610001-01462.Peer-Reviewed Original Research
Clinical Trials
Current Trials
Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma
HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028Recruiting ParticipantsPhase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
HIC ID2000032539RoleSub InvestigatorPrimary Completion Date05/19/2029Recruiting ParticipantsParallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsRandomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026Recruiting ParticipantsA Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
HIC ID2000031542RoleSub InvestigatorPrimary Completion Date01/31/2026Recruiting Participants
Clinical Care
Overview
Elan Gorshein, DO (doctor of osteopathic medicine), MPH, specializes in treating patients with hematologic malignancies at Smilow Cancer Hospital.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as bone marrow and immune system cells, and include leukemia, lymphoma, and multiple myeloma. Osteopathic medicine focuses on treating the patient as a whole rather than addressing specific symptoms.
Dr. Gorshein has a JD (juris doctor) degree and is an assistant professor of clinical medicine (hematology) at Yale School of Medicine.
Clinical Specialties
Hematologic Oncology; Thoracic Oncology
Fact Sheets
Thrombocytopenia
Learn More on Yale MedicineCOVID-19
Learn More on Yale MedicineCoronavirus
Learn More on Yale MedicineMyeloproliferative Neoplasms
Learn More on Yale Medicine
Yale Medicine News
News
News
- April 02, 2024
Yale Department of Internal Medicine Promotions and Appointments (April 2024)
- June 08, 2023Source: Cancer Network
The ‘Golden Age’ of Daratumumab: Highlights From an Expert Panel on Multiple Myeloma
- June 23, 2021
Smilow Cancer Hospital Care Center at Guilford physicians make ‘Top Docs’ list in Connecticut
- September 30, 2018
Smilow Cancer Hospital Care Center - Guilford
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.